An Open-Label, Multinational, Multicenter, Follow-Up Study to Evaluate the Long-Term Safety and Efficacy of Brivaracetam, Used at a Flexible Dose up to a Maximum of 150 mg/day, in Subjects aged 16 years or older suffering from Epilepsy